American Mothers Seriously Concerned About Childhood Allergies, Siemens Survey Reveals
and Allergy Foundation of America states that ... help prevent the progression of allergies to asthma
-- a disease associated with significant economic ... Academy on an Aging Society, 2000. From the asthma
and Allergy Foundation
of America. Allergy ...
Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
... for Mometasone Furoate/Formoterol Combination for asthma
KENILWORTH, N.J., May 19 ... combination therapies for the treatment of asthma
and chronic obstructive pulmonary disease (COPD). ... will allow us to focus our efforts within the asthma
and COPD market," said Thomas P. Koestler, Ph.D., ...
New Study Funded By the National Institutes of Health (NIH) Finds Masimo SpCO(R) May Provide a Noninvasive Measure of Acute Asthma Severity in Children
... (SpCO) may help clinicians better assess acute asthma
severity during and after treatment. The study ... (PAS) Annual Meeting on May 5, 2009.(1)
is a life-threatening inflammatory disease of the ... However, a common challenge for children with asthma
is the requirement of a forced expiratory test ...
SiliconSky GPS Designs First AGPS-Enabled Asthma Inhaler for Landmark Research Program
... GPS, designs and develops a GPS-enabled asthma
inhaler that will help a cutting edge epidemiology researcher to better understand asthma
Red Lodge, ... and beta-manufacturing of the first-of-its-kind asthma
inhaler enabled with GPS tracking for a ...
Pharmaxis Appoints French Distributor for Aridol(TM)
... its French marketer and distributer for the asthma
diagnostic tool, Aridol.
Praxis ... asthma."
The total population affected by asthma
in France is approximately 3.1
million. The ... Initiative for Asthma
guidelines, and in the U.S. asthma
Management Guidelines. It is one of the
FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
... 2007 for the long-term maintenance treatment of asthma
in patients 12 years of age and older.(2)
... for the long-term maintenance treatment of asthma
in patients 12 years of age and older.(2) ... or potentially life-threatening episodes of asthma
Patients who are receiving ...
MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs
... Unit Dose Budesonide (UDB) for children
and MAP0004 for the acute treatment of migraine. ... continue to make good progress with our Phase 3 asthma
programs and look forward to ... progress coupled with our recently
partnership with AstraZeneca highlights the value ...
MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
... a Phase 2 clinical trial in patients with chronic asthma
determine the safety of subcutaneous dosing of ... IL-5.
MedImmune's Clinical Development in asthma
MedImmune has multiple approaches in ... the subject of this press
Pharmaxis Research Programs Highlighted at European Respiratory Society Congress
... and exercise challenge in children with asthma
-- Association between mannitol dry powder ... -- Exercise-induced asthma, acute severe asthma
and allergic rhinitis in children -- ... challenge test (Aridol) during optimized asthma
treatment in adolescents with exercise ...
New consensus on work-related asthma
... on the diagnosis and treatment of work-related asthma
(WRA), a chronic respiratory condition that includes occupational asthma
and work-exacerbated asthma
(WEA) and affects as many as 25 percent of adults ...
Video: ASMANEX(R) TWISTHALER(R) 110 MCG (Mometasone Furoate Inhalation Powder) is Now Available Nationwide for the Maintenance Treatment of Asthma in Children Ages 4 to 11
... is indicated for the maintenance treatment of asthma
prophylactic therapy in patients four years of ... It is
not indicated for the relief of sudden asthma
symptoms or in children less
than 4 years of ... a new treatment option to help manage
as back-to-school season approaches. Studies show ...
Lotus Pharmaceuticals Announces Second Quarter 2008 Results
... production rights for Laevo-Bambutero, an asthma
drug -- Placed a down payment for land rights in ... in China. Laevo-Bambutero is a more
drug than a number of alternative drugs that ... patent and exclusive production rights to a
drug, Laevo-Bambutero, which we plan to launch in ...
Asthma Uncontrolled in More Than 40 Percent of Adults With the Disease, New Landmark Survey Shows
... from Phase One of Two-Phase Examination of U.S. asthma
RESEARCH TRIANGLE PARK, N.C. and ... Nearly half of adult Americans with asthma
and more than a quarter of
children with asthma
who responded to a nationally representative ...
Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
... and TORONTO, May 20 /PRNewswire/ --
Patients with asthma
not adequately controlled on the ... 36 percent less likely to suffer a severe asthma
by treatment with oral or ... in one device to help prevent and
Pharmaxis' Aridol Authorised for Sale in Germany
... in the diagnosis and assessment of severity
and how much medication should be used."
As ... in the GINA Report of
Global Strategy for asthma
Management and Prevention, the US ... on the Management of Asthma
and the Australian asthma
Management Handbook. To find out more ...
Aridol(TM) Endorsed by International Olympic Committee
... in their just-released IOC Consensus
Statement on asthma
in Elite Athletes, for athletes competing in the
Beijing Olympics. The prevalence of asthma
in elite athletes has grown
exponentially in ... found no
evidence that the commonly used asthma
treatments known as beta-2 agonists
conferred any ...
Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
... airway inflammation poised to transform asthma
management for improved control.
MENLO PARK, ... indicator of airway inflammation and asthma
Insight system is a highly accurate ... techniques used to diagnose,
monitor and treat asthma
are costly, time-consuming and ...
Allergy Standards LTD to Attend 2008 American Academy of Allergy, Asthma and Immunology Conference
... at the 2008 American Academy of
and Immunology (AAAAI) Conference to be held ... those working and
conducting research work in the asthma
and allergy spaces," said Dr. John
McKeon, CEO of ... control standards to reduce everyday exposure to asthma
allergy triggers and dangerous toxins. ...
FDA Grants Market Clearance to Aerocrine Inc.'s NIOX MINO(R): a New Hand-Held Device to Measure Airway Inflammation in Asthma
... helping them improve how they treat asthma
(Photo: ... patients' response to therapy
and the risk of an asthma
relapse. Moreover, physicians will be able ... the United States
represents a major advance in asthma
management, because for the first
time, doctors ...
LPGA Pro, Jill McGill, Encourages Indoor and Outdoor Allergy Sufferers to Challenge Their Course
... Association (LPGA) player Jill McGill and the asthma
Allergy Foundation of America (AAFA) have ... to see my
physician. Now I'm teaming up with the asthma
and Allergy Foundation of
America to help educate ... and in New York
(NYSE: SNY ).
and Allergy Foundation of America (AAFA), ...
Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor
... Inhalation Aerosol for the
treatment of asthma
and in the Omnaris(TM) Nasal Spray for the ... in the ALVESCO(R) Inhalation
Aerosol for asthma
and the Omnaris(TM) Nasal Spray for allergic ... (ICS) are regarded today as the gold standard
and allergic rhinitis therapy. They inhibit the ...
ALVESCO(R) Gains FDA Approval for the U.S. Market
Maintenance and Prophylactic Treatment of asthma
in Patients 12 years of ... United States for the maintenance
treatment of asthma
and as prophylactic therapy in adult and ... treatment
option to help patients control their asthma
and improve their quality of
life, and will be an ...
Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
... provides additional treatment option for asthma
patients not fully controlled on other ... for the prevention and chronic
treatment of asthma
in patients 12 years of age and older. "We are ... for the prophylaxis and chronic treatment
in adults and children 12 years of age and older. ...
Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management
... Phadia US Inc. announced today
that The National asthma
Education and Prevention Program (NAEPP) ... and potential severity of asthma
and that allergy testing is
necessary to educate ... symptom control. "The role of allergy testing in asthma
management is important
information for patients, ...
Schering-Plough Reports Financial Results for 2009 Second Quarter
... pharmaceutical market, in July of ASMANEX (mometasone furoate) for asthma
and REMERON (mirtazapine) for depression; these approvals bring the number ... commercialization of fixed-dose combination therapies for the treatment of asthma
and chronic obstructive pulmonary disease. (Announced May 19)
Knocking the Wind Out of Asthmatics: Help from Hippocrates
and allergy sufferers have an alternative to Singulair and Zicam - The ... requesting the manufacturers of Singulair, a popular leukotriene blocking asthma
and allergy drug, to upgrade their warning against psychotic side effects. ...
HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for Novel Influenza A (H1N1)
... clinical trials. FluMist should not be administered to any individual with asthma
and to children less than five years of age with recurrent wheezing unless ... the potential risk. Do not administer FluMist to individuals with severe asthma
or active wheezing.
If Guillain-Barre syndrome has occurred with ...
U.S. FDA Accepts Aridol(TM) New Drug Application for Review
... in the diagnosis of patients with symptoms of or
suggestive of asthma." asthma
affects more than 34 million people in the U.S.
with an annual economic ... included in the Global Initiative for Asthma
guidelines, and in the U.S. asthma
Management Guidelines. It is one of the
tests recommended by the World ...
Amira Initiates Phase I Clinical Trial of Novel DP2 Antagonist
... Proof of Mechanism of a Potential Oral Antagonist for the Treatment of asthma
SAN DIEGO, April 20 /PRNewswire/ -- Amira Pharmaceuticals, ... data for AM211.
"There remains a great deal of unmet medical need in asthma
and COPD, and we look forward to exploring AM211's potential as a new ...
Magellan to Receive Frost & Sullivan 2009 North American Product Innovation Award; Three-Minute LeadCare(R) II Test Identifies Children with Lead Poisoning
... and their families. The societal cost is also staggering. Even though asthma
affects many more children, the total economic costs pale in comparison: nationally, it is estimated at $2 billion for asthma
and $43 billion for lead. That is because the negative effects of even ...
Novartis/Schering-Plough's Drug Will Replace AstraZeneca's Symbicort as Decision Resources' Clinical Gold Standard by 2012 for the Treatment of Asthma
... Resources' proprietary clinical gold standard by 2012 for the treatment of asthma
due to its once-daily dosing competitive advantage. In fact, because none ... to increase patient compliance. Patient compliance is important because asthma
is a chronic disease that requires consistent administration of ...
Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
... announced they have
entered into a license agreement for a promising new asthma
discovered at the University of Tennessee Health Science ... one step closer to a treatment that could
reduce -- and even prevent -- asthma
attacks in children. We are delighted to
have their support as we continue ...
Aerovance Appoints Babatunde A. Otulana, M.D., as Chief Medical Officer
... as it moves forward with the development of AerovantTM for uncontrolled asthma
and AerodermTM for severe atopic eczema. He has more than 20 years of ... provide new tools for physicians in the management of intractable severe asthma
and atopic dermatitis respectively, in millions of patients."
Inverseon's Asthma Therapy Receives Notice of Allowance; Clinical Trial Highlighted in Lancet
... for asthma. Additionally, a comment highlighting Inverseon's clinical asthma
study was published in the January 10, 2009 issue of The Lancet.
"To ... billion dollar products."
"The Lancet Comment on Inverseon's human asthma
study combined with the notice of allowance from the US Patent Office ...
Visualizing asthma-causing immune cells at work
... responses in the lungs and airways of mice with a disease that mimics asthma
(experimental allergic airway inflammation); they hope that these ... an appropriate optical sensor they might improve our ability to diagnose asthma
and assess treatment efficacy.
Video: New Survey Shows Three in Four School Nurses Have Students at Risk for Severe Allergic Reactions Who Do Not Bring Auto-Injectable Epinephrine to School
... Ms. Garcia said.
About the NASN Survey
NASN's "Management of asthma
and Anaphylaxis in Schools Survey" was an
anonymous online survey ... the California
School Nurse Organization (CSNO) and West Coast Allergy and asthma
(WestCAAN). Dr. Larry Posner and Nancy Spradling, executive ...
Cadient Group Recognized with Five Awards at 14th Annual Communicator Awards
... site, each of whom shares a specific story about managing a child's asthma
and provides more information about the seriousness of asthma
and the need for caregivers to proactively control their child's ...
MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
... in late stage development for the potential treatment of
and migraine respectively. MAP Pharmaceuticals' pipeline
also includes a drug candidate in early clinical development for the
treatment of asthma
and chronic obstructive pulmonary disease.
Additional information about ...
Nebulized Formoterol Fumarate Has Comparable Pharmacokinetic and Pharmacodynamic Profile to Dry Powder Formulation
... the safety of another LABA
(salmeterol) or placebo added to usual asthma
therapy showed an increase in
asthma-related deaths in patients receiving ... The safety and efficacy of
Perforomist(TM) Inhalation Solution in asthma
has not been established.
In COPD clinical trials, the most common ...
New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
... involving 832
patients ages 18 years and older with moderate to severe asthma
previously treated with ICS(1). After a 10-14 day run-in on ... a combination therapy indicated for the long-term
maintenance treatment of asthma
in patients 12 years of age and older(2).
Administered twice daily, ...